Drugs / barzolvolimab
Drug research

barzolvolimab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as CDX-0159

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaNCT06445023Celldex TherapeuticsPhase 3Active not recruiting2026-10Estimated
A Study of CDX-0159 in Patients With Chronic Inducible UrticariaNCT05405660Celldex TherapeuticsPhase 2Completed2024-06-12Actual
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaNCT07256392Celldex TherapeuticsPhase 3Enrolling by invitation2028-09Estimated
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)NCT06455202Celldex TherapeuticsPhase 3Active not recruiting2026-10Estimated
A Study of Barzolvolimab in Patients With Prurigo NodularisNCT06366750Celldex TherapeuticsPhase 2Active not recruiting2026-03-17Actual
A Study of CDX-0159 in Patients With Eosinophilic EsophagitisNCT05774184Celldex TherapeuticsPhase 2Completed2025-06-04Actual
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaNCT05368285Celldex TherapeuticsPhase 2Completed2023-09-28Actual

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.